Aprea Therapeutics, Inc. (NASDAQ:APRE) Short Interest Update

Aprea Therapeutics, Inc. (NASDAQ:APRE) saw a large increase in short interest in June. As of June 30th, there was short interest totalling 22,200 shares, an increase of 13.3% from the June 15th total of 19,600 shares. Based on an average daily volume of 9,300 shares, the short-interest ratio is currently 2.4 days. Currently, 0.5% of the shares of the stock are sold short.

Aprea Therapeutics Price Performance

Shares of APRE opened at $3.99 on Wednesday. Aprea Therapeutics has a one year low of $2.83 and a one year high of $8.85. The company has a 50-day moving average of $4.53 and a two-hundred day moving average of $5.51. The stock has a market cap of $21.67 million, a price-to-earnings ratio of -1.20 and a beta of 1.04.

Aprea Therapeutics (NASDAQ:APRE) last posted its quarterly earnings results on Tuesday, May 14th. The company reported ($0.67) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.78) by $0.11. The business had revenue of $0.38 million during the quarter. Aprea Therapeutics had a negative net margin of 1,317.82% and a negative return on equity of 56.78%. Analysts anticipate that Aprea Therapeutics will post -2.57 earnings per share for the current year.

Analysts Set New Price Targets

Several brokerages have commented on APRE. HC Wainwright reiterated a “buy” rating and issued a $20.00 target price on shares of Aprea Therapeutics in a report on Monday, June 24th. Wedbush reiterated an “outperform” rating and issued a $11.00 target price on shares of Aprea Therapeutics in a report on Tuesday, May 14th.

About Aprea Therapeutics

Aprea Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors.